CODING THE HYBRID PROTEIN RECOMBINANT PLASMID DNA PERIG-PGS, ABLE TO AUTOCATALIC SPLITTING WITH FORMATION OF THE PIGASTINE ANTI-ANGIOGENIC PEPTIDE - DERIVATIVE OF THE HUMAN PIGMENTAL EPITHELY GROWTH FACTOR FRAGMENT [44-77], STRAIN ESCHERICHIA COLI BL21(DE3)/PERIG-PGS - PRODUCER OF THE SAID PROTEIN, AND THE RECOMBINANT ANTI-ANGIOGENIC PEPTIDE PRODUCTION METHOD Russian patent published in 2018 - IPC C12N15/62 C12N15/70 C12N1/21 C12P21/02 C12R1/19 

FIELD: genetic engineering.

SUBSTANCE: invention relates to the field of genetic engineering, specifically to the anti-angiogenic proteins recombinant production, and can be used in medicine. Developed is the pERIG-PGS recombinant plasmid DNA, in the Escherichia coli cells ensuring the GyrA-PGS hybrid protein synthesis, containing the Mxe GyrA modified mini-intein and the Pigastin anti-angiogenic peptide, the human pigment epithelial growth factor [44-77] fragment derivative with the Pro-Gly-Pro sequence attached to the C-terminus. By the E. coli strain BL21(DE3) cells transformation with the pERIG-PGS recombinant plasmid DNA, a strain is obtained E.coli BL21(DE3)/pERIG-PGS, producing the GyrA-PGS hybrid polypeptide. Anti-angiogenic peptide Pigastin production method comprises the producer strain culturing E.coli BL21(DE3)/pERIG-PGS, destruction of the cellular biomass, the fusion protein isolation from the inclusion bodies, its autocatalytic splitting and the target peptide chromatographic purification.

EFFECT: invention allows to produce the anti-angiogenic peptide Pigastin with high yield and by simplified technology.

3 cl, 5 dwg, 4 ex